---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-016982"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2023-10-30T23:59:59+00:00"
generated_at: "2026-06-09T06:02:44.230374+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# NeuroBo Pharmaceuticals appoints Marshall H. Woodworth as Acting CFO effective Oct 27, 2023

## Summary
- Marshall H. Woodworth appointed Acting CFO, Principal Financial and Principal Accounting Officer, effective October 27, 2023.
- Woodworth previously served as CFO of Nevakar Inc. (2017-2023), Braeburn Pharmaceuticals, and Furiex Pharmaceuticals.
- Compensation: $375 per hour paid to WhiteCap Search Holdings LLC under an engagement agreement; no family relationships or material interests.
- Woodworth entered a Proprietary Information and Invention Assignment Agreement with NeuroBo; no other arrangements in connection with appointment.

## SEC filing metadata
- accession: 0001558370-23-016982
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2023-10-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837023016982/0001558370-23-016982-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837023016982/nrbo-20231025x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-016982
- JSON: https://secwatch.observer/filing/0001558370-23-016982.json
- Plain text: https://secwatch.observer/filing/0001558370-23-016982.txt

## Key facts
- Executive change
  Marshall H. Woodworth was appointed as Acting Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer at MetaVia Inc..
  - Action: appointed
  - Role: Acting Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
  source text: On October 25, 2023, the Board of Directors (the “Board” ) of NeuroBo Pharmaceuticals, Inc. (the “Company” ) appointed Mr. Marshall H. Woodworth as the Company’s Acting Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective as of October 27, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638287/000155837023016982/0001558370-23-016982-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.